Outcomes from a randomized management trial revealed yesterday in JAMA Community Open present that contributors who obtained mRNA COVID-19 and inactivated influenza vaccines concurrently had no extra adversarial results than those that obtained the 2 pictures sequentially, 1 or 2 weeks aside.
The examine included 335 individuals who had been vaccinated from October 2021 to June 2023 at considered one of three US examine websites. All contributors had been ages 5 years and older and supposed to obtain each flu and mRNA COVID-19 vaccines. The common age of contributors was 33.4 years, and 63% had been feminine.
In whole, 169 obtained the vaccines concurrently, whereas 166 obtained them sequentially.
The authors stated the principle outcomes of the examine had been reactogenicity, together with fever, chills, muscle aches, and/or joint ache of reasonable or better severity inside 7 days after vaccination. Critical adversarial occasions and adversarial occasions of particular curiosity had been assessed for 121 days.
Over half of contributors (57.0%) reported a historical past of SARS-CoV-2 an infection or had detectible antibodies to the virus on the time of examine enrollment.
Good security information
The authors discovered that the proportion of examine contributors with the first composite reactogenicity end result within the simultaneous group (25.6%) was noninferior to the proportion within the sequential group (31.3%).
“Fewer than 13% of contributors in both group (simultaneous, 14 [8.3%]; sequential, 21 [12.6%]) had a extreme response for any of the solicited reactions, and no contributors sought medical consideration for a solicited response,” the authors wrote.
Equally, there was no distinction between the 2 teams in health-related high quality of life indexes.
This trial lends assist to the choice of simultaneous administration of those vaccines, which is a technique to attain excessive ranges of vaccination protection.
“This trial lends assist to the choice of simultaneous administration of those vaccines, which is a technique to attain excessive ranges of vaccination protection throughout anticipated durations of elevated influenza and SARS-CoV-2 virus transmission,” the authors concluded.
